59.67 +0.68 (1.16%)
After hours: 4:15PM EST
|Bid||0.00 x 0|
|Ask||0.00 x 0|
|Day's Range||58.82 - 59.99|
|52 Week Range||42.31 - 64.60|
|PE Ratio (TTM)||219.29|
|Earnings Date||Apr 17, 2018 - Apr 23, 2018|
|Forward Dividend & Yield||1.12 (1.86%)|
|1y Target Est||68.22|
BSX Stock Recovers after a Robust 4Q17: What's to Come? On February 1, 2018, Boston Scientific (BSX) announced its 4Q17 and 2017 earnings results. Boston Scientific’s 2017 performance was affected by a series of events within the company as well as macroeconomic developments such as the recall of its Lotus devices, the hurricanes and wildfires in the United States, and the US tax reform.
BSX Stock Recovers after a Robust 4Q17: What's to Come? On January 24, 2018, Boston Scientific (BSX) announced an investment deal, including an acquisition option, with Millipede, a California-based, privately-held company. The deal strengthens Boston Scientific’s position in the mitral valve therapy market for the treatment of MR (mitral regurgitation) patients.
A trial under way in federal court in Philadelphia is testing the power of U.S. competition regulators to crack down on drug makers’ alleged moves to thwart the sale of low-cost generics.
BSX Stock Recovers after a Robust 4Q17: What's to Come? In December 2017, the Tax Cuts and Jobs Act was passed in the US Senate. The healthcare industry has seen the impact of the tax reform, with most US healthcare companies reporting one-time financial effects on their balance sheets.
BSX Stock Recovers after a Robust 4Q17: What's to Come? In 4Q17, Boston Scientific’s (BSX) Rhythm Management segment registered sales of ~$565 million, a YoY (year-over-year) rise of ~5.4% on a reported basis. Its operational sales growth came in at ~3% in 4Q17.
BSX Stock Recovers after a Robust 4Q17: What's to Come? In 4Q17, Boston Scientific’s (BSX) Cardiovascular business segment reported sales of $913 million, representing above-market YoY (year-over-year) growth of ~8.7%. The segment’s IC (interventional cardiology) division reported sales of $636 million in 4Q17, which represented a YoY rise of ~8.8%, including the impact of ~2.8% from its acquisition of Symetis in May 2017.
BSX Stock Recovers after a Robust 4Q17: What's to Come? In 4Q17, Boston Scientific’s (BSX) Cardiovascular segment registered strong YoY (year-over-year) sales growth of ~8.7% on a reported basis. The segment’s PI (peripheral interventions) division came in at $277 million, registering a YoY rise of 8.4%, whereas the IC (interventional cardiology) division reported sales of $636 million, a YoY rise of ~8.8%. The operational sales growth of BSX’s Cardiovascular segment came in at ~6.8%.
BSX Stock Recovers after a Robust 4Q17: What's to Come? In 4Q17, Boston Scientific’s (BSX) MedSurg segment witnessed double-digit YoY (year-over-year) growth of ~14.2%, on a reported basis. The segment’s operational sales growth came in at ~12.8%, whereas it grew ~11.2% on an organic basis.
Abbott Laboratories (NYSE:ABT) files its latest 10-K with SEC for the fiscal year ended on December 31, 2017.
Measuring Abbott Laboratories’s (NYSE:ABT) track record of past performance is a valuable exercise for investors. It allows us to understand whether or not the company has met or exceed expectations,Read More...
BSX Stock Recovers after a Robust 4Q17: What's to Come? Boston Scientific released its 4Q17 and 2017 earnings results on February 1, 2018. During its earnings release, the company announced that it expected to relaunch its Lotus device in European and US markets in 2019.
ABBOTT PARK, Ill., Feb. 16, 2018 /PRNewswire/ -- The board of directors of Abbott (ABT) today declared a quarterly common dividend of 28 cents per share. This marks the 377th consecutive quarterly dividend to be paid by Abbott since 1924. The cash dividend is payable May 15, 2018, to shareholders of record at the close of business on April 13, 2018.
NEW YORK, NY / ACCESSWIRE / February 15, 2018 / U.S. markets rallied sharply from early losses Wednesday as inflation fears appear to be easing on Wall Street. The Dow Jones Industrial Average jumped 1.03 ...
Valentine's Day celebrates all types of romantic arrangements. Last year, we highlighted some of our favorites. But as happens with love, some flames have faded, some have rekindled and some now burn in ...